InspireMD Announces Appointment of Katie Arnold to Board of Directors
May 12, 2021 06:00 ET | Source: InspireMD Inc. InspireMD Inc. Tel Aviv, ISRAEL
TEL AVIV, Israel, May 12, 2021 (GLOBE NEWSWIRE) InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced it has appointed seasoned marketing executive Kathryn (Katie) Arnold to its Board of Directors. With more than two decades of strategy and commercialization experience within the medical device industry, Ms. Arnold joins as the company advances global commercialization and enrollment in the U.S. IDE trial of its novel CGuard EPS technology.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
InspireMD Announces Appointment of Katie Arnold to Board of Directors
InspireMD Inc.May 12, 2021 GMT
TEL AVIV, Israel, May 12, 2021 (GLOBE NEWSWIRE) InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced it has appointed seasoned marketing executive Kathryn (Katie) Arnold to its Board of Directors. With more than two decades of strategy and commercialization experience within the medical device industry, Ms. Arnold joins as the company advances global commercialization and enrollment in the U.S. IDE trial of its novel CGuard EPS technology.